Immunological alteration of leukemic cells in vivo after treatment with an antitumor drug.
L1210 leukemia was transplanted serially in CDF(1) mice treated with 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DIC, NSC 45388). After four different lines (C lines) had been treated for several generations, a marked increase in survival time of untreated mice was observed. In contrast, mice treated with DIC or immunosuppressed with cyclophosphamide succumbed earlier with generalized leukemia. Furthermore, a C line showed unusually high sensitivity to chemotherapeutic treatment with 1,3 bis(2-chloroethyl)-1-nitrosourea. The data suggest that C lines acquired strong antigenicity for CDF(1) and DBA/2 hosts. DIC treatment may have selected highly antigenic variants or induced somatic mutations resulting in the appearance of strong new transplantation antigen(s).
D000818:Animals; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D007093:Imidazoles / Q000627:therapeutic use*; D007939:Leukemia L1210 / Q000188:drug therapy*; D008136:Longevity; D008297:Male; D051379:Mice; D009603:Nitroso Compounds / Q000627:therapeutic use; D014181:Transplantation Immunology; D014508:Urea / Q000627:therapeutic use
D007093:Imidazoles; D009603:Nitroso Compounds; D003520:Cyclophosphamide; D014508:Urea